MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR) - SARS-CoV-2 THERAPEUTICS RESEARCH RELATED ACTIVITIES

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: TIMOTHY  STEDMAN
Organization: AMERICAN TYPE CULTURE COLLECTION
Fiscal Year: 2022
Award: $2,924,707
Funding agency: National Institute of Allergy and Infectious Diseases

This contract provides unique and quality-assured infectious reagents and resources to the scientific community for use in basic research and product development. The scope of this contract includes the acquisition, authentication, production, preservation, storage, and distribution of research and reference reagents to the research community. These reagents span the pathogens in the Division of Microbiology and Infectious Diseases portfolio, and include the National Institutes of Allergy and Infectious Disease (NIAID) Category A, B and C Priority Pathogens and emerging infectious diseases.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Basic Research><Basic Science><COVID-19><COVID-19 therapeutics><COVID-19 virus><COVID19><COVID19 therapeutics><COVID19 virus><CV-19><CV19><Categories><CoV-2><CoV2><Communicable Diseases><Communities><Contracting Opportunities><Contracts><Development and Research><Emerging Communicable Diseases><Emerging Infectious Diseases><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Microbiology><NIAID><National Institute of Allergy and Infectious Disease><Production><R & D><R&D><Reagent><Research><Research Resources><Resources><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 therapeutics><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Therapeutic Human Experimentation><Therapeutic Research><Wuhan coronavirus><biological research><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 therapeutics><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 virus><coronavirus infectious disease-19><depository><hCoV19><nCoV2><pathogen><preservation><priority pathogen><product development><repository><research and development><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus>